TABLE 1.
Patient characteristics
| All patients (N = 169) | |
|---|---|
| Age (years) | 77.7 ± 6.2 |
| Male gender | 155 (91.7) |
| Type of ATTR CM | |
| Hereditary | 25 (14.8) |
| Wildtype | 129 (76.3) |
| ATTR CM type not determined | 15 (8.9) |
| Co‐morbidities a | |
| Any | 163 (96.4) |
| Atrial fibrillation | 116 (68.6) |
| Hypertension | 80 (47.3) |
| Ischaemic heart disease | 34 (20.1) |
| Gastrointestinal disease | 20 (11.8) |
| Spinal stenosis | 19 (11.2) |
| Diabetes | 17 (10.1) |
| Diagnostic delay b | 1.7 ± 3.3 |
| Time since ATTR CM diagnosis (years) | 3.1 ± 1.8 |
| <2 | 71 (42.0) |
| >2–4 | 72 (42.6) |
| >4–6 | 17 (10.1) |
| >6 | 8 (4.8) |
| Missing or not applicable/available | 1 (0.6) |
| NYHA stage | |
| I | 13 (7.7) |
| II | 92 (54.4) |
| III | 59 (34.9) |
| IV | 3 (1.8) |
| Missing or not applicable/available | 2 (1.2) |
| NAC stage | |
| 1 | 90 (53.3) |
| 2 | 43 (25.4) |
| 3 | 31 (18.3) |
| Missing or not applicable/available | 5 (3.0) |
| Current medical treatment for ATTR CM | |
| ATTR CM modifying treatment | 14 (8.3) |
| Symptomatic treatment c | 55 (32.5) |
| No ATTR CM treatment | 1 (0.6) |
| Participation in RCT | 98 (58.0) |
| Missing or not applicable/available | 1 (0.6) |
Data are presented as n (%) or mean ± SD.
RCT, randomized clinical trial; NAC, National Amyloidosis Centre; NYHA, New York Heart Association; 99mTc‐DPD, 99mTechnetium labelled 3,3‐diphosphono‐1,2‐propanodicarboxylic acid.
a
Co‐morbidities were defined as those medically treated at time of inclusion independent of ATTR CM or non‐ATTR CM origin.
b
Diagnostic delay is defined as time from first cardiological examination to the diagnostic date of biopsy and/or 99mTc‐DPD scintigraphy.
c
Patients were defined as receiving symptomatic treatment if they only received symptomatic treatment.